Raxibacumab for anthrax

Medical Letter on Drugs and Therapeutics

Volumn 55, Issue 1413, 2013, Pages 27-28

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DIPHENHYDRAMINE; DOXYCYCLINE; LEVOFLOXACIN; PLACEBO; RAXIBACUMAB;

ANTHRAX; ARM PAIN; ARTHRALGIA; CELL DEATH; CONTINUOUS INFUSION; COUGHING; DRUG EFFICACY; DRUG HALF LIFE; EXPERIMENTAL MONKEY; FEVER; HEADACHE; HUMAN; INJECTION SITE REACTION; LEG PAIN; MALAISE; MYALGIA; NAUSEA; NONHUMAN; NOTE; PHARYNGITIS; PROPHYLAXIS; PRURITUS; RABBIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SOMNOLENCE; SURVIVAL RATE; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTHRAX; ANTIBODIES, MONOCLONAL; DRUG APPROVAL; HUMANS; POST-EXPOSURE PROPHYLAXIS; RESPIRATORY TRACT INFECTIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84875486984     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. JG Wright et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010; 59(RR-6):1.
2. Drugs and vaccines against biological weapons. Med Lett Drugs Ther 2001; 43:87.
3. S Mazumdar. Raxibacumab. MAbs 2009; 1:531.
4. TS Migone et al. Raxibacumab for the treatment of inhalational anthrax. N Eng J Med 2009; 361:135.
5. A Corey et al. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/raxibacumab-treated New Zealand white rabbits. Toxins (Basel) 2013; 5:120.